Additionally, although the functional consequences of LAG-3 blockade in CLL have mainly been studied for T cells [256], it has recently been shown that in vitro treatment of CLL cells with the LAG-3-blocking mAb relatlimab (BMS-986016) restores NK cell proliferation and antitumor activity and in combination with lenalidomide significantly increases rituximab-mediated ADCC of NK cells and IL-2 production by T cells [257]. Here, IL2 is linked to B-cell chronic lymphocytic leukemia.